PF 6741086

Drug Profile

PF 6741086

Alternative Names: PF-06741086; PF-6741086

Latest Information Update: 30 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Antifibrinolytic agents; Blood coagulation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 08 Mar 2017 Phase-II clinical trials in Haemophilia in Chile (IV) (NCT02974855)
  • 08 Mar 2017 Phase-II clinical trials in Haemophilia in Chile (SC) (NCT02974855)
  • 03 Dec 2016 Pharmacodynamic results from a preclinical trial in Haemophilia reported at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top